FindTrial
Sign In

A study of anti-nephrin autoantibodies in the diagnosis, treatment, and prognosis of podocytopathies

Preliminary study of anti-nephrin antibody in podocytosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093169
Enrollment
Unknown
Registered
2024-11-29
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

podocytopathies

Interventions

MCD group:None
FSGS group:None
Disease control group:None
Healthy control group:None

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with MCD and FSGS confirmed by renal biopsy; More complete clinicopathological data; Sign informed consent voluntarily. Disease control: patients with membranous nephropathy (anti PLA2R antibody positive), diabetes nephropathy, lupus, IgA nephropathy, and polycystic kidney disease; Voluntarily sign the informed consent form. Healthy control: Healthy volunteers, no underlying diseases, normal physical examination, age and gender matched with the case group.

Exclusion criteria

Exclusion criteria: Secondary podocytopaties (obesity, hypertension, hepatitis and HIV-positive and tumor patients); Patients with known genetic basis or pathogenic variants found by genetic testing (whole genome sequencing excluded hereditary FSGS in patients under 30 years of age with steroid-resistant NS).

Design outcomes

Primary

MeasureTime frame
Anti-nephrin autoantibodies;—

Countries

China

Contacts

Public ContactQINGGANG LI

Chinese PLA General Hospital

lqgbj301@126.com+86 159 1068 8792

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026